Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model | Zendy

Mahmoud A. Ghannoum | Zendy; N. Isham | Zendy; D. Angulo | Zendy; Katyna Borroto–Esoda | Zendy; Stephen Barat | Zendy; L. Long | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model

Author(s) -

Mahmoud A. Ghannoum,

N. Isham,

D. Angulo,

Katyna Borroto–Esoda,

Stephen Barat,

L. Long

Publication year - 2020

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00854-20

Subject(s) - candida auris , guinea pig , pharmacokinetics , dosing , in vivo , medicine , skin infection , colonization , biology , dermatology , microbiology and biotechnology , antifungal , staphylococcus aureus , bacteria , genetics

Candida auris has been shown to have a high risk of skin colonization in hospitalized patients, possibly contributing to nosocomial spread. In a guinea pig skin model, animals were evaluated for clinical appearance, tissue fungal burden, histology, and pharmacokinetics. Oral dosing with 10 mg/kg ibrexafungerp (IBX) reduced the severity of lesions and significantly reduced the C. auris fungal burden in infected animals compared with untreated controls. This indicates promise for use of IBX in controlling skin infection and colonization of hospitalized patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research